{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:16:04Z","timestamp":1767485764042,"version":"3.48.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-025-06463-2","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T07:52:34Z","timestamp":1766044354000},"page":"6187-6196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quantitative assessment of innate myeloid cells in myelofibrosis: insights into myeloid and plasmacytoid dendritic cell depletion and disease progression"],"prefix":"10.1007","volume":"104","author":[{"given":"Nath\u00e1lia Aparecida Cavalcante","family":"Silva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F\u00e1bio Pinotti","family":"Guirao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00edriam Cristina Rodrigues","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego Alonso Olavarr\u00eda","family":"Bernal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura Coutinho","family":"Vassalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex Freire","family":"Sandes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"6463_CR1","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O et al (2022) The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia 36:1703\u20131719. https:\/\/doi.org\/10.1038\/s41375-022-01613-1","journal-title":"Leukemia"},{"key":"6463_CR2","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","volume":"5","author":"M Kleppe","year":"2015","unstructured":"Kleppe M, Kwak M, Koppikar P et al (2015) JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov 5:316\u2013331. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0736","journal-title":"Cancer Discov"},{"key":"6463_CR3","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1182\/blood-2016-10-695957","volume":"129","author":"E Rumi","year":"2017","unstructured":"Rumi E, Cazzola M (2017) Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood 129:680\u2013692. https:\/\/doi.org\/10.1182\/blood-2016-10-695957","journal-title":"Blood"},{"key":"6463_CR4","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1038\/bcj.2011.39","volume":"1","author":"KL Rice","year":"2011","unstructured":"Rice KL, Lin X, Wolniak K et al (2011) Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms. Blood Cancer J 1:e40. https:\/\/doi.org\/10.1038\/bcj.2011.39","journal-title":"Blood Cancer J"},{"key":"6463_CR5","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1182\/blood.2020007897","volume":"137","author":"W Xiao","year":"2021","unstructured":"Xiao W, Chan A, Waarts MR et al (2021) Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia. Blood 137:1377\u20131391. https:\/\/doi.org\/10.1182\/blood.2020007897","journal-title":"Blood"},{"key":"6463_CR6","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.3324\/haematol.2020.253740","volume":"106","author":"L Zalma\u00ef","year":"2021","unstructured":"Zalma\u00ef L, Viailly P-J, Biichle S et al (2021) Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape. Haematologica 106:3056\u20133066. https:\/\/doi.org\/10.3324\/haematol.2020.253740","journal-title":"Haematologica"},{"key":"6463_CR7","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1038\/s41375-019-0447-3","volume":"33","author":"N Lucas","year":"2019","unstructured":"Lucas N, Duchmann M, Rameau P et al (2019) Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia. Leukemia 33:2466\u20132480. https:\/\/doi.org\/10.1038\/s41375-019-0447-3","journal-title":"Leukemia"},{"key":"6463_CR8","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/bjh.18632","volume":"200","author":"S El Hussein","year":"2023","unstructured":"El Hussein S, Wang W (2023) Plasmacytoid dendritic cells in the setting of myeloid neoplasms: diagnostic guide to challenging pathologic presentations. Br J Haematol 200:545\u2013555. https:\/\/doi.org\/10.1111\/bjh.18632","journal-title":"Br J Haematol"},{"key":"6463_CR9","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1182\/blood-2015-01-620781","volume":"125","author":"D Selimoglu-Buet","year":"2015","unstructured":"Selimoglu-Buet D, Wagner-Ballon O, Saada V et al (2015) Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. Blood 125:3618\u20133626. https:\/\/doi.org\/10.1182\/blood-2015-01-620781","journal-title":"Blood"},{"key":"6463_CR10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/cyto.b.22176","volume":"106","author":"S Tarfi","year":"2024","unstructured":"Tarfi S, Kern W, Goulas E et al (2024) Technical, gating and interpretation recommendations for the partitioning of circulating monocyte subsets assessed by flow cytometry. Cytometry B Clin Cytom 106:203\u2013215. https:\/\/doi.org\/10.1002\/cyto.b.22176","journal-title":"Cytometry B Clin Cytom"},{"key":"6463_CR11","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/bjh.15061","volume":"183","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Shah S, Mudireddy M et al (2018) Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis. Br J Haematol 183:835\u2013838. https:\/\/doi.org\/10.1111\/bjh.15061","journal-title":"Br J Haematol"},{"key":"6463_CR12","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/modpathol.2012.165","volume":"26","author":"L Boiocchi","year":"2013","unstructured":"Boiocchi L, Espinal-Witter R, Geyer JT et al (2013) Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease. Mod Pathol Off J U S Can Acad Pathol Inc 26:204\u2013212. https:\/\/doi.org\/10.1038\/modpathol.2012.165","journal-title":"Mod Pathol Off J U S Can Acad Pathol Inc"},{"key":"6463_CR13","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, Caramazza D, Vaidya R et al (2011) DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol Off J Am Soc Clin Oncol 29:392\u2013397. https:\/\/doi.org\/10.1200\/JCO.2010.32.2446","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"6463_CR14","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1038\/leu.2017.169","volume":"31","author":"F Passamonti","year":"2017","unstructured":"Passamonti F, Giorgino T, Mora B et al (2017) A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia 31:2726\u20132731. https:\/\/doi.org\/10.1038\/leu.2017.169","journal-title":"Leukemia"},{"key":"6463_CR15","doi-asserted-by":"publisher","unstructured":"Stewart CC, Stewart SJ (2001) Immunophenotyping. Curr Protoc Cytom Chap 6:Unit 6.2. https:\/\/doi.org\/10.1002\/0471142956.cy0602s00","DOI":"10.1002\/0471142956.cy0602s00"},{"key":"6463_CR16","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.1182\/blood-2008-06-158386","volume":"112","author":"J-J Lataillade","year":"2008","unstructured":"Lataillade J-J, Pierre-Louis O, Hasselbalch HC et al (2008) Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence. Blood 112:3026\u20133035. https:\/\/doi.org\/10.1182\/blood-2008-06-158386","journal-title":"Blood"},{"key":"6463_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1586\/ehm.09.17","volume":"2","author":"L Varricchio","year":"2009","unstructured":"Varricchio L, Mancini A, Migliaccio AR (2009) Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis. Expert Rev Hematol 2:315\u2013334. https:\/\/doi.org\/10.1586\/ehm.09.17","journal-title":"Expert Rev Hematol"},{"key":"6463_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/nyas.14028","volume":"1466","author":"K Kaushansky","year":"2020","unstructured":"Kaushansky K, Zhan H (2020) The marrow stem cell niche in normal and malignant hematopoiesis. Ann N Y Acad Sci 1466:17\u201323. https:\/\/doi.org\/10.1111\/nyas.14028","journal-title":"Ann N Y Acad Sci"},{"key":"6463_CR19","doi-asserted-by":"publisher","first-page":"683401","DOI":"10.3389\/fimmu.2021.683401","volume":"12","author":"DAC Fisher","year":"2021","unstructured":"Fisher DAC, Fowles JS, Zhou A, Oh ST (2021) Inflammatory pathophysiology as a contributor to myeloproliferative neoplasms. Front Immunol 12:683401. https:\/\/doi.org\/10.3389\/fimmu.2021.683401","journal-title":"Front Immunol"},{"key":"6463_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3978\/j.issn.2306-9759.2016.02.03","volume":"3","author":"A Agarwal","year":"2016","unstructured":"Agarwal A, Morrone K, Bartenstein M et al (2016) Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-\u03b2. Stem Cell Investig 3:5. https:\/\/doi.org\/10.3978\/j.issn.2306-9759.2016.02.03","journal-title":"Stem Cell Investig"},{"key":"6463_CR21","doi-asserted-by":"publisher","unstructured":"Geyer HL, Dueck AC, Scherber RM, Mesa RA (2015) Impact of inflammation on myeloproliferative neoplasm symptom development. Mediators Inflamm 2015:e284706. https:\/\/doi.org\/10.1155\/2015\/284706","DOI":"10.1155\/2015\/284706"},{"key":"6463_CR22","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/cbin.11084","volume":"43","author":"T Suboti\u010dki","year":"2019","unstructured":"Suboti\u010dki T, Mitrovi\u0107 Ajti\u0107 O, Beleslin-\u010coki\u0107 BB et al (2019) IL-6 stimulation of DNA replication is JAK1\/2 mediated in cross-talk with hyperactivated ERK1\/2 signaling. Cell Biol Int 43:192\u2013206. https:\/\/doi.org\/10.1002\/cbin.11084","journal-title":"Cell Biol Int"},{"key":"6463_CR23","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/ni.2077","volume":"12","author":"MT Pallotta","year":"2011","unstructured":"Pallotta MT, Orabona C, Volpi C et al (2011) Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol 12:870\u2013878. https:\/\/doi.org\/10.1038\/ni.2077","journal-title":"Nat Immunol"},{"key":"6463_CR24","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.3892\/or_00001028","volume":"24","author":"H Tanaka","year":"2010","unstructured":"Tanaka H, Shinto O, Yashiro M et al (2010) Transforming growth factor \u03b2 signaling inhibitor, SB-431542, induces maturation of dendritic cells and enhances anti-tumor activity. Oncol Rep 24:1637\u20131643. https:\/\/doi.org\/10.3892\/or_00001028","journal-title":"Oncol Rep"},{"key":"6463_CR25","doi-asserted-by":"publisher","first-page":"e70738","DOI":"10.1371\/journal.pone.0070738","volume":"8","author":"JK Nieminen","year":"2013","unstructured":"Nieminen JK, Niemi M, Sipponen T et al (2013) Dendritic cells from crohn\u2019s disease patients show aberrant STAT1 and STAT3 signaling. PLoS ONE 8:e70738. https:\/\/doi.org\/10.1371\/journal.pone.0070738","journal-title":"PLoS ONE"},{"key":"6463_CR26","doi-asserted-by":"publisher","first-page":"e1345402","DOI":"10.1080\/2162402X.2017.1345402","volume":"6","author":"M Romano","year":"2017","unstructured":"Romano M, Sollazzo D, Trabanelli S et al (2017) Mutations in JAK2 and calreticulin genes are associated with specific alterations of the immune system in myelofibrosis. Oncoimmunology 6:e1345402. https:\/\/doi.org\/10.1080\/2162402X.2017.1345402","journal-title":"Oncoimmunology"},{"key":"6463_CR27","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1007\/s00277-020-04069-4","volume":"99","author":"D Tremblay","year":"2020","unstructured":"Tremblay D, Schwartz M, Bakst R et al (2020) Modern management of splenomegaly in patients with myelofibrosis. Ann Hematol 99:1441\u20131451. https:\/\/doi.org\/10.1007\/s00277-020-04069-4","journal-title":"Ann Hematol"},{"key":"6463_CR28","doi-asserted-by":"publisher","first-page":"750346","DOI":"10.3389\/fimmu.2021.750346","volume":"12","author":"D Cattaneo","year":"2021","unstructured":"Cattaneo D, Iurlo A (2021) Immune dysregulation and infectious complications in MPN patients treated with JAK inhibitors. Front Immunol 12:750346. https:\/\/doi.org\/10.3389\/fimmu.2021.750346","journal-title":"Front Immunol"},{"key":"6463_CR29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.exphem.2021.06.004","volume":"100","author":"A Heine","year":"2021","unstructured":"Heine A, Wolf AM, Schlaweck S et al (2021) Pacritinib protects dendritic cells more efficiently than ruxolitinib. Exp Hematol 100:37\u201340. https:\/\/doi.org\/10.1016\/j.exphem.2021.06.004","journal-title":"Exp Hematol"},{"key":"6463_CR30","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1038\/leu.2016.155","volume":"30","author":"J Rudolph","year":"2016","unstructured":"Rudolph J, Heine A, Quast T et al (2016) The JAK inhibitor ruxolitinib impairs dendritic cell migration via off-target Inhibition of ROCK. Leukemia 30:2119\u20132123. https:\/\/doi.org\/10.1038\/leu.2016.155","journal-title":"Leukemia"},{"key":"6463_CR31","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.3389\/fonc.2019.01186","volume":"9","author":"EM Elli","year":"2019","unstructured":"Elli EM, Barat\u00e8 C, Mendicino F et al (2019) Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib. Front Oncol 9:1186. https:\/\/doi.org\/10.3389\/fonc.2019.01186","journal-title":"Front Oncol"},{"key":"6463_CR32","doi-asserted-by":"publisher","first-page":"204062072311547","DOI":"10.1177\/20406207231154706","volume":"14","author":"M Marchetti","year":"2023","unstructured":"Marchetti M, Salmanton-Garc\u00eda J, El-Ashwah S et al (2023) Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry. Ther Adv Hematol 14:20406207231154706. https:\/\/doi.org\/10.1177\/20406207231154706","journal-title":"Ther Adv Hematol"},{"key":"6463_CR33","doi-asserted-by":"publisher","first-page":"50","DOI":"10.4103\/ijn.IJN_222_19","volume":"31","author":"M Atlani","year":"2021","unstructured":"Atlani M, Sharma T, Joshi D, Kumar A (2021) Immune complex associated glomerulonephritis in a patient with prefibrotic primary myelofibrosis: a case report. Indian J Nephrol 31:50\u201353. https:\/\/doi.org\/10.4103\/ijn.IJN_222_19","journal-title":"Indian J Nephrol"},{"key":"6463_CR34","first-page":"234","volume":"112","author":"C Lu","year":"2018","unstructured":"Lu C, Wu X, Wen H et al (2018) Primary myelofibrosis but not autoimmune myelofibrosis accompanied by sj\u00f6gren\u2019s syndrome and primary biliary cirrhosis in a patient with trisomy 8 mosaic: a case report and literature review. Clin Exp Rheumatol 36 Suppl 112:234\u2013236","journal-title":"Clin Exp Rheumatol 36 Suppl"},{"key":"6463_CR35","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.3390\/ijms23063177","volume":"23","author":"C Cumbo","year":"2022","unstructured":"Cumbo C, Anelli L, Zagaria A et al (2022) Second cancer onset in myeloproliferative neoplasms: what, when, why? Int J Mol Sci 23:3177. https:\/\/doi.org\/10.3390\/ijms23063177","journal-title":"Int J Mol Sci"},{"key":"6463_CR36","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1038\/s41375-018-0027-y","volume":"32","author":"AR Landtblom","year":"2018","unstructured":"Landtblom AR, Bower H, Andersson TM-L et al (2018) Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients. Leukemia 32:2203\u20132210. https:\/\/doi.org\/10.1038\/s41375-018-0027-y","journal-title":"Leukemia"},{"key":"6463_CR37","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nri3865","volume":"15","author":"M Swiecki","year":"2015","unstructured":"Swiecki M, Colonna M (2015) The multifaceted biology of plasmacytoid dendritic cells. Nat Rev Immunol 15:471\u2013485. https:\/\/doi.org\/10.1038\/nri3865","journal-title":"Nat Rev Immunol"},{"key":"6463_CR38","doi-asserted-by":"publisher","first-page":"843342","DOI":"10.3389\/fimmu.2022.843342","volume":"13","author":"T Chang","year":"2022","unstructured":"Chang T, Yang J, Deng H et al (2022) Depletion and dysfunction of dendritic cells: understanding SARS-CoV-2 infection. Front Immunol 13:843342. https:\/\/doi.org\/10.3389\/fimmu.2022.843342","journal-title":"Front Immunol"},{"key":"6463_CR39","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","volume":"20","author":"SK Wculek","year":"2020","unstructured":"Wculek SK, Cueto FJ, Mujal AM et al (2020) Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol 20:7\u201324. https:\/\/doi.org\/10.1038\/s41577-019-0210-z","journal-title":"Nat Rev Immunol"},{"key":"6463_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41423-021-00741-5","volume":"19","author":"TL Murphy","year":"2022","unstructured":"Murphy TL, Murphy KM (2022) Dendritic cells in cancer immunology. Cell Mol Immunol 19:3\u201313. https:\/\/doi.org\/10.1038\/s41423-021-00741-5","journal-title":"Cell Mol Immunol"},{"key":"6463_CR41","doi-asserted-by":"publisher","first-page":"981","DOI":"10.3390\/cancers16050981","volume":"16","author":"L Hato","year":"2024","unstructured":"Hato L, Vizcay A, Eguren I et al (2024) Dendritic cells in Cancer immunology and immunotherapy. Cancers 16:981. https:\/\/doi.org\/10.3390\/cancers16050981","journal-title":"Cancers"},{"key":"6463_CR42","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1111\/bjh.17850","volume":"196","author":"M Strickland","year":"2022","unstructured":"Strickland M, Quek L, Psaila B (2022) The immune landscape in BCR-ABL negative myeloproliferative neoplasms: inflammation, infections and opportunities for immunotherapy. Br J Haematol 196:1149\u20131158. https:\/\/doi.org\/10.1111\/bjh.17850","journal-title":"Br J Haematol"},{"key":"6463_CR43","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s12032-022-01825-6","volume":"39","author":"VL Bassan","year":"2022","unstructured":"Bassan VL, Barretto GD, de Almeida FC et al (2022) Philadelphia-negative myeloproliferative neoplasms display alterations in monocyte subpopulations frequency and immunophenotype. Med Oncol Northwood Lond Engl 39:223. https:\/\/doi.org\/10.1007\/s12032-022-01825-6","journal-title":"Med Oncol Northwood Lond Engl"},{"key":"6463_CR44","doi-asserted-by":"publisher","first-page":"e584","DOI":"10.1038\/bcj.2017.66","volume":"7","author":"MM Patnaik","year":"2017","unstructured":"Patnaik MM, Timm MM, Vallapureddy R et al (2017) Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis. Blood Cancer J 7:e584. https:\/\/doi.org\/10.1038\/bcj.2017.66","journal-title":"Blood Cancer J"},{"key":"6463_CR45","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.exphem.2013.12.002","volume":"42","author":"R Campanelli","year":"2014","unstructured":"Campanelli R, Rosti V, Fois G et al (2014) CD14(bright)CD16(low) intermediate monocytes expressing Tie2 are increased in the peripheral blood of patients with primary myelofibrosis. Exp Hematol 42:244\u2013246. https:\/\/doi.org\/10.1016\/j.exphem.2013.12.002","journal-title":"Exp Hematol"},{"key":"6463_CR46","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s11899-021-00660-2","volume":"17","author":"E Morsia","year":"2022","unstructured":"Morsia E, Gangat N (2022) Myeloproliferative neoplasms with monocytosis. Curr Hematol Malig Rep 17:46\u201351. https:\/\/doi.org\/10.1007\/s11899-021-00660-2","journal-title":"Curr Hematol Malig Rep"},{"key":"6463_CR47","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.humpath.2018.10.026","volume":"85","author":"Z Hu","year":"2019","unstructured":"Hu Z, Ramos CEB, Medeiros LJ et al (2019) Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic leukemia from primary myelofibrosis with monocytosis. Hum Pathol 85:290\u2013298. https:\/\/doi.org\/10.1016\/j.humpath.2018.10.026","journal-title":"Hum Pathol"},{"key":"6463_CR48","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","volume":"36","author":"P Guglielmelli","year":"2018","unstructured":"Guglielmelli P, Lasho TL, Rotunno G et al (2018) MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol Off J Am Soc Clin Oncol 36:310\u2013318. https:\/\/doi.org\/10.1200\/JCO.2017.76.4886","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06463-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06463-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06463-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:15:05Z","timestamp":1767485705000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06463-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":48,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6463"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06463-2","relation":{},"ISSN":["1432-0584"],"issn-type":[{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"28 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the institutional review board of the Universidade Federal de S\u00e3o Paulo, and all patients gave their informed consent prior to entering the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}